Results 291 to 300 of about 1,172,272 (355)

Reprogrammed Lipid Metabolism-Associated Therapeutic Vulnerabilities in Prostate Cancer. [PDF]

Int J Mol Sci
Parupathi P, Devarakonda LS, Francois E, Amjed M, Kumar A.   +4 more
europepmc   +1 more source

Spatial Transcriptomics Reveals Transcriptomic and Immune Microenvironment Reprogramming during Thyroid Carcinoma Dedifferentiation

Advanced Science, EarlyView.
Spatial transcriptomic analysis of Anaplastic thyroid carcinoma (ATC)‐differentiated thyroid carcinoma (DTC) coexisting tumors reveals that coexisting DTC regions with ATC‐like genomic alterations undergo sequential transcriptomic reprogramming and immune microenvironment remodeling, ultimately evolving into a full ATC pathological phenotype.
Kang Ning, Bu Zou, Yongchao Yu, Taonong Cai, Zhenyu Luo, Yu Guo, Yi Wu, Xiujiao Shen, Hao Li, Mengyuan Fang, Jian Bu, Han Hong, Zan Jiao, Tong Wu, Yulong Wang, Tianrun Liu, Weichao Chen, Wanming Hu, Mingjie Jiang, Ankui Yang   +19 more
wiley   +1 more source

Prostate Cancer Immunotherapy: Time to Move Beyond Checkpoint Inhibitors. [PDF]

Immunotargets Ther
Abel M, Warner AB, Karzai F, Madan RA.
europepmc   +1 more source

Real‐Time Tracking of ASCT2‐Mediated Glutamine Uptake in Living Tumors With a Bioorthogonal Bioluminescent Probe

Advanced Science, EarlyView.
A bioluminescent probe, BLGLN, comprising BL568 and ASCT2‐uptaken AA201, enables real‐time monitoring and evaluation of ASCT2‐mediated glutamine uptake rates in living tumors via Staudinger ligation, aiding tumor metabolism studies and targeted therapeutics.
Bing‐Jun Zhou, Ji‐Lei Zhao, Fan Yin, Wen‐Da Chen, Yi Sun, Ying‐Ying Ren, Yi‐Min Chen, Tian Xie, Chong Duan, Jian‐Liang Zhou   +9 more
wiley   +1 more source

Is it time for Canada to revisit its approach to prostate cancer screening? [PDF]

Lancet Reg Health Am
Nguyen DD, Lofters A, Wallis CJD, Zlotta AR, Fleshner NE, Trinh QD, Finelli A, Rosella LC, Detsky AS, Roobol MJ, Kulkarni GS.   +10 more
europepmc   +1 more source

Cytotoxicity of Esculetin Compared with Vinblastine and Paclitaxel in PC-3 Prostate Cancer Cells. [PDF]

Curr Oncol
García-Pérez AI, Rubio V, Herráez A, Puebla L, Diez JC.   +4 more
europepmc   +1 more source

Drug targets in prostate cancer: an appetite for KLK2-mediated destruction. [PDF]

Clin Cancer Res
Blinka S, Yu EY.
europepmc   +1 more source

Rural and Urban Differences in Prostate Cancer Recurrence.

JAMA Netw Open
Balmaceda JB, Katz AJ, Cao Y, Kane K, Chen MW, Usinger D, Shen X.   +6 more
europepmc   +1 more source